On January 21, 2021, Dr. Kerry Blanchard, CEO of Everest Medicines, a leading bio-pharmaceutical innovative company involved in late-stage clinical development in China, was awarded the 13th Health China Top 10 Pharmaceutical Business Leaders Award. Sponsored and appraised by People's Daily Health APP and Health Times under People's Daily, the award aims to recognize business leaders who have a significant impact and leadership role in pharmaceutical innovation, maintain a good social image, are actively fulfilling their corporate social responsibility and participate in the Healthy China strategy.

Under the leadership of Dr. Kerry Blanchard, Everest Medicines has a promising portfolio of eight innovative drug candidates in four major therapeutic areas. In particular, sacituzumab govitecan-hziy, an innovative drug for the treatment of metastatic triple negative breast cancer, has been included in the latest edition of the Chinese Guidelines for Standardized Diagnosis and Treatment of Advanced Breast Cancer, restoring new hope of life for countless critically ill breast cancer patients. Nefecon, an innovative drug for IgA nephropathy, has been recognized by the Centre of Drug Evaluation of the National Medical Products Administration as a breakthrough therapy that could be a solution for a disease with of no approved. Dr. Kerry Blanchard has been thus hailed by the reviewing committee as an explorer of innovative drugs in China. 

Commenting on the award, Dr. Kerry Blanchard said, “I am personally humbled to receive this award and this recognition by the industry at large is great encouragement for Everest Medicines as a whole. Everest Medicines has made great progress in 2020. We had a successful initial public offering last October and we also advanced the clinical development of our eight innovative pipeline assets in each of our four major areas: oncology, cardio-renal disease, immunology and anti-infectious diseases. This award would not have been possible without the joint efforts of everyone in Everest Medicines. The recognition from the industry inspires us to be even more focused and determined as we move forward. Our base in China is the foundation for our growth. We continue to put patients first in our actions and strive to meet the unmet medical needs of doctors and patients by bringing more innovative drugs with greater efficacy to China patients.”

Dr. Kerry Blanchard has more than 30 years of experience in oncology R&D with deep experience in drug hunting and clinical development. He served as a hematology-oncology physician scientist at Harvard Medical School and Louisiana State University. With a commitment to finding ways to help more patients, he entered the field of pharmaceutical drug research and development where he worked in leading pharmaceutical companies leading the development of new pharmaceutical drugs.

Founded in 2007, the "Health China Forum" has been held for 13 sessions and is regarded as a benchmark of China's innovative pharmaceutical industry. The 13th Health China Forum (2020) selected the top 10 pharmaceutical industrial leaders of the year based on three major criteria: scientific and technological innovation, industry status, and social reputation. The results were presented at the end of a three-month process of determining the criteria, advisory panel consultations, organizing committee discussions, online voting and peer reviews. The other business leaders in the industry who received the award came from nine well-known Chinese pharmaceutical companies such as Sinopharm and Fosun Pharma.

About Everest Medicines:

Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. For more information, please visit their website at www.everestmedicines.com.

For more information, please contact:
Edmond Lococo
Managing Director
ICR Asia
+86 (10) 6583-7510
edmond.lococo@icrinc.com